Increasing evidence indicates that a “one-size-fits-all” approach with the use of antithrombotic therapy in patients after percutaneous intervention could lead to either suboptimal efficacy or prohibitively high bleeding in specific cohorts of patients. Moreover, clinical features, procedural variables and pharmacodynamic response to antithrombotic therapy may significantly affect the individual-patient response to this therapy. A personalization of antithrombotic therapy is needed to optimize the balance between ischemic and bleeding events.
A number of antithrombotic strategies have been proposed during the past decades, aiming at either reducing ischemic or bleeding events, among cohorts of patients requiring percutaneous interventions. Careful risk stratification at a single patient level represents the foundation of a personalized selection of antithrombotic therapy in these patients. This can be achieved by an integrated assessment of three key factors: bleeding risk, ischemic risk and responsiveness to antithrombotic agents.
This Research Topic will discuss the role of platelet therapy and provide new data in support of the implementation of precision medicine for antithrombotic therapy before and after percutaneous interventions.
Conflicts of Interest:
Dr. Angiolillo - declares that he has received consulting fees or honoraria from Abbott, Amgen, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, and Sanofi. D.J.A. also declares that his institution has received research grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, Renal Guard Solutions and Scott R. MacKenzie Foundation.
Increasing evidence indicates that a “one-size-fits-all” approach with the use of antithrombotic therapy in patients after percutaneous intervention could lead to either suboptimal efficacy or prohibitively high bleeding in specific cohorts of patients. Moreover, clinical features, procedural variables and pharmacodynamic response to antithrombotic therapy may significantly affect the individual-patient response to this therapy. A personalization of antithrombotic therapy is needed to optimize the balance between ischemic and bleeding events.
A number of antithrombotic strategies have been proposed during the past decades, aiming at either reducing ischemic or bleeding events, among cohorts of patients requiring percutaneous interventions. Careful risk stratification at a single patient level represents the foundation of a personalized selection of antithrombotic therapy in these patients. This can be achieved by an integrated assessment of three key factors: bleeding risk, ischemic risk and responsiveness to antithrombotic agents.
This Research Topic will discuss the role of platelet therapy and provide new data in support of the implementation of precision medicine for antithrombotic therapy before and after percutaneous interventions.
Conflicts of Interest:
Dr. Angiolillo - declares that he has received consulting fees or honoraria from Abbott, Amgen, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, and Sanofi. D.J.A. also declares that his institution has received research grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, Renal Guard Solutions and Scott R. MacKenzie Foundation.
